2. Search Result
Search Result
Results for "

anticance

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Peptides

5

Inhibitory Antibodies

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0523
    Gallic acid
    5+ Cited Publications

    3,4,5-Trihydroxybenzoic acid

    		 COX Reactive Oxygen Species Apoptosis Ferroptosis Endogenous Metabolite Metabolic Disease Cancer
    Gallic acid (3,4,5-Trihydroxybenzoic acid) is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2) . Gallic acid has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities .
    Gallic acid
  • HY-N0523A
    Gallic acid hydrate
    5+ Cited Publications

    3,4,5-Trihydroxybenzoic acid hydrate
    Gallic acid (3,4,5-Trihydroxybenzoic acid) hydrate is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2) . Gallic acid hydrate has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities .
    Gallic acid hydrate
  • HY-147080
    Avacincaptad pegol sodium

    ARC1905

    		 Complement System Others
    Avacincaptad pegol (ARC1905) is an anti-C5 RNA aptamer that inhibits the cleavage of complement factor 5 (C5) into C5a and C5b. Avacincaptad pegol is being used for the study of age-related macular degeneration (AMD).
    Avacincaptad pegol sodium
  • HY-P99322
    Tesidolumab

    LFG316; Anti-Human C5 Recombinant Antibody

    		 Complement System Inflammation/Immunology
    Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
    Tesidolumab
  • HY-P10146
    Ac-LETD-CHO

    		Caspase Cancer
    Ac-LETD-CHO is a caspases 8 inhibitor. Ac-LETD-CHO has specific inhibition to casp-8 with an IC50 value of 6.71 nM. Ac-LETD-CHO can be used for the research of anticancer .
    Ac-LETD-CHO
  • HY-P99786
    Pozelimab

    REGN3918

    		 Complement System Metabolic Disease
    Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
    Pozelimab
  • HY-147281
    BAY 1135626

    		Drug-Linker Conjugates for ADC Cancer
    BAY 1135626 is used to synthesize BAY 1129980, and use to anti-tumor research. BAY 1129980 is a Auristatin-based anti-C4.4A (LYPD3) antibody–agent conjugate (ADC), is used to non–small cell lung cancer (NSCLC) research .
    BAY 1135626
  • HY-N0523S
    Gallic acid-d2

    3,4,5-Trihydroxybenzoic acid-d2

    		 Apoptosis COX Ferroptosis Endogenous Metabolite Reactive Oxygen Species
    Gallic acid-d2 is the deuterium labeled Gallic acid[1]. Gallic acid (3,4,5-Trihydroxybenzoic acid) is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2)[2]. Gallic acid has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities[3].
    Gallic acid-d2
  • HY-P99520
    Vilobelimab

    CaCP-29, IFX-1

    		 Complement System SARS-CoV Infection Inflammation/Immunology
    Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
    Vilobelimab
  • HY-P990091
    Riliprubart

    SAR 445088

    		 Complement System Inflammation/Immunology
    Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .
    Riliprubart

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: